Nanobiotix S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K is filed by Nanobiotix S.A., a foreign private issuer headquartered in Paris, France. The report covers the month of March 2026 and incorporates by reference a press release dated March 31, 2026 (Exhibit 99.1). The registrant files annual reports under Form 20-F.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a notification of a press release rather than a detailed financial statement.
Material Changes
The filing text does not provide data to compare against prior periods. No material changes in financial position are detailed within the provided text.
Guidance, Outlook, and Risks
Management commentary, guidance, outlook, risks, contingencies, and unusual items are not detailed in the provided text. The content refers readers to the attached press release (Exhibit 99.1) for the substance of the announcement.
Key Facts for Investors to Verify
- Review the full text of the press release dated March 31, 2026 (Exhibit 99.1) to understand the specific announcement triggering this filing.
- Verify if the press release contains updates on clinical trials, regulatory approvals, or partnership agreements, which are typical for this company.
- Check subsequent filings for any financial impact resulting from the March 31, 2026 announcement.